Revbio, Inc.

Revbio, Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

RevBio was started with one goal in mind—to end medicine’s 50 year search for a biocompatible bone adhesive. Effective for bone-to-bone as well as bone-to-metal wet field applications, Tetranite® is a revolutionary biomaterial that promises to transform bone repair—for both patients and clinicians. Inspired by the marine animal the sandcastle worm, Tetranite is simple chemistry. Bioengineered from the worm’s secreted protein, our synthetic adhesive is the only patented biomaterial which satisfies both the required and desired properties for a bone adhesive: wet field performance, multi-surface bonding, rapid mechanical stability, and controlled biodegradability. The properties of Tetranite™ include the ability to provide immediate fixation of bone to bone and bone to metal. This adhesive has been shown in multiple animal studies to be a non-toxic and effective way of repairing bone fractures and defects as well as securing implant devices. Existing data has also shown that Tetranite™ is reabsorbed and replaced with new bone during the natural process of bone remodeling by acting as a scaffold to facilitate bone growth over time.

Company Details

Employees
32
Founded
-
Address
600 Suffolk Street,
Industry
Medical Equipment Manufacturing
NAICS
Medical Equipment and Supplies Manufacturing
Surgical and Medical Instrument Manufacturing
Surgical Appliance and Supplies Manufacturing
Dental Equipment and Supplies Manufacturing
Ophthalmic Goods Manufacturing
Dental Laboratories
HQ
Lowell, MA
Looking for a particular Revbio, Inc. employee's phone or email?

Revbio, Inc. Questions

News

NIA Small Business Showcase: RevBio - National Institute on Aging (.gov)

NIA Small Business Showcase: RevBio National Institute on Aging (.gov)

RevBio Receives a $2.2 Million Phase II NIH Grant to Further Develop the Minimally Invasive Use of TETRANITE - Business Wire

RevBio Receives a $2.2 Million Phase II NIH Grant to Further Develop the Minimally Invasive Use of TETRANITE Business Wire

RevBio Receives a $2.2 Million Phase II NIH Grant to Further Develop the Minimally Invasive Use of TETRANITE® to Treat Complex Spine Fractures - Orthopedics This Week

RevBio Receives a $2.2 Million Phase II NIH Grant to Further Develop the Minimally Invasive Use of TETRANITE® to Treat Complex Spine Fractures Orthopedics This Week

RevBio Issued a Key Patent for its Regenerative Bone Adhesive Technology by the United States Patent and Trademark Office - Nasdaq

RevBio Issued a Key Patent for its Regenerative Bone Adhesive Technology by the United States Patent and Trademark Office Nasdaq

RevBio Receives Both FDA Approval to Expand its Clinical Trial and CMS Reimbursement for its Regenerative Bone Adhesive for Cranial Flap Fixation - Yahoo Finance

RevBio Receives Both FDA Approval to Expand its Clinical Trial and CMS Reimbursement for its Regenerative Bone Adhesive for Cranial Flap Fixation Yahoo Finance

RevBio Initiates its Pivotal Clinical Trial in Europe for its Dental Implant Stabilization Product - Business Wire

RevBio Initiates its Pivotal Clinical Trial in Europe for its Dental Implant Stabilization Product Business Wire

RevBio Expands Globally into the United Kingdom with its Second Cranial Flap Fixation Clinical Trial for its Regenerative Bone Adhesive - Business Wire

RevBio Expands Globally into the United Kingdom with its Second Cranial Flap Fixation Clinical Trial for its Regenerative Bone Adhesive Business Wire

RevBio secures green light from FDA to expand bone adhesive clinical trial - Medical Device Network

RevBio secures green light from FDA to expand bone adhesive clinical trial Medical Device Network

RevBio Bone Adhesive to Fly on SpaceX CRS-26 - International Space Station National Laboratory

RevBio Bone Adhesive to Fly on SpaceX CRS-26 International Space Station National Laboratory

LaunchPad Medical Rebrands as RevBio and Launches an Updated Website - PR Newswire

LaunchPad Medical Rebrands as RevBio and Launches an Updated Website PR Newswire

RevBio Receives FDA Approval to Conduct its Second U.S.-Based Clinical Trial for Dental Implant Stabilization - BioSpace

RevBio Receives FDA Approval to Conduct its Second U.S.-Based Clinical Trial for Dental Implant Stabilization BioSpace

RevBio Issued a Key Patent for its Regenerative Bone Adhesive Technology by the United States Patent and Trademark Office - Business Wire

RevBio Issued a Key Patent for its Regenerative Bone Adhesive Technology by the United States Patent and Trademark Office Business Wire

RevBio Receives FDA Approval to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation - BioSpace

RevBio Receives FDA Approval to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation BioSpace

RevBio Receives Both FDA Approval to Expand its Clinical Trial and CMS Reimbursement for its Regenerative Bone Adhesive for Cranial Flap Fixation - Business Wire

RevBio Receives Both FDA Approval to Expand its Clinical Trial and CMS Reimbursement for its Regenerative Bone Adhesive for Cranial Flap Fixation Business Wire

RevBio Receives a $2.4 Million NIH Grant to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation and Enrolls First Five Patients - Business Wire

RevBio Receives a $2.4 Million NIH Grant to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation and Enrolls First Five Patients Business Wire

RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product - Business Wire

RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product Business Wire

RevBio Receives NIH Grant to Explore the Treatment of Vertebral Compression Fractures with Its Regenerative Bone Adhesive Technology - Business Wire

RevBio Receives NIH Grant to Explore the Treatment of Vertebral Compression Fractures with Its Regenerative Bone Adhesive Technology Business Wire

RevBio Awarded a $3.4 Million NIH Grant for Its Novel Regenerative Bone Adhesive to Treat Complex Fractures - Business Wire

RevBio Awarded a $3.4 Million NIH Grant for Its Novel Regenerative Bone Adhesive to Treat Complex Fractures Business Wire

RevBio: $2.4 Million NIH Grant Awarded From NINDS - Pulse 2.0

RevBio: $2.4 Million NIH Grant Awarded From NINDS Pulse 2.0

RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product - BioSpace

RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product BioSpace

Top Revbio, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant